The Gulf countries are no longer betting solely on AI: biotechnology and quantum computing are among the growing areas of interest for their sovereign wealth funds. This pivot is part of a diversification strategy: financing technologies with high research intensity, some of which could influence long-term energy demand. The question is whether this strategy can produce genuine industrial capacity, or whether it will remain a portfolio of financial assets without local anchoring.
The Essentials
- Gulf sovereign wealth funds are targeting biotech and quantum computing in 2026. Biotech already has industrial capacity in several segments, while quantum computing remains primarily at a development and demonstration stage.
- Several regional startups have received support from local funds, a sign that the Gulf is now financing local players as well as stakes in foreign companies.
- The model rests on a structural bet: diversifying the economy toward research-intensive technologies and developing non-petroleum capabilities, following a pattern comparable to the one Singapore pursued by developing its pharmaceutical production from 1972 onward and strengthening its biomedical strategy in the 2000s.
- Success depends on several institutional conditions: local training, appropriate regulation, and capacity to retain talent.
Oil Rents Converted into Venture Capital
Gulf sovereign wealth funds manage significant capital. Mubadala (Abu Dhabi), Saudi Arabia’s Public Investment Fund, and the Qatar Investment Authority have long placed this capital in real estate, infrastructure, and Western financial markets. Their allocations toward technology sectors with high research intensity include AI, biotech, and other technological domains.
This shift is rooted in an arithmetic reality. Petroleum revenues depend on a resource whose long-term demand is uncertain. Investing in technologies that accelerate the energy transition, including biofuels derived from synthetic biology, amounts to hedging both sides of the same bet: if the transition moves quickly, these countries will have the technologies that replace oil; if it moves slowly, they will still have oil. The strategy is more a sophisticated financial hedge than an ideological bet on the end of hydrocarbons.
Quantum computing fits into this same logic. The most immediate applications concern logistical optimization, materials modeling, and cryptography. For economies seeking to build competitive manufacturing sectors, early access to quantum computing capabilities represents a potential advantage in markets where competitiveness rests on computational precision: fine chemicals, pharmaceuticals, energy network management.
Mastiska and the Signal of Local Ecology
Mastiska’s fundraising deserves attention, less for its size than for what it signifies. Mastiska’s funding to develop AI chips and sovereign accelerators illustrates an orientation toward supporting regional enterprises. The support of local sovereign wealth funds for regional companies fits into a localization strategy already formalized at least since 2021.
Until now, the Gulf’s technological strategy was primarily acquisitive: taking stakes in companies already established elsewhere, in Boston, San Francisco, or Tel Aviv. Supporting Mastiska amounts to betting on the construction of a local entrepreneurial ecosystem, with all that implies: probable failures, long delays, and a need for patience that sovereign wealth funds do not always naturally practice.
Abu Dhabi has also invested in genome sequencing capabilities at the population scale, notably through public health initiatives led by the government. The genome of the Gulf population is underrepresented in major global databases, dominated by North American and European cohorts. Building a local genomic database opens medical perspectives specific to this population, but also a competitive advantage for companies that will develop diagnostics or treatments adapted to this population. Dependence on foreign data carries risks analogous to those experienced by Latin American research in relation to external funding: whoever controls the data partly controls the scientific agenda.
The Singapore Model, Its Strengths and Limitations
The analogy with Singapore between 1990 and 2010 circulates often in discussions about Gulf diversification. It deserves to be examined seriously rather than used as a reassuring shortcut.
Singapore built a leading pharmaceutical industry by combining several precise elements: an intellectual property policy attractive to multinationals, massive investments in local scientific training through the National University and Nanyang, the creation of dedicated industrial clusters, and a state bureaucracy capable of implementing long-term policies without being captured by short-term interests. GlaxoSmithKline, Novartis, and Pfizer established significant production capacities in Singapore because the entire system was coherent and predictable.
Gulf countries share certain comparable assets: abundant capital, explicit political will, and governments capable of holding a course over several electoral cycles, or rather in their absence. The main difference lies in the human capital base. Singapore in 1990 already had an educational fabric and a scientific diaspora it could repatriate. Gulf universities were improving but starting from lower levels. Abu Dhabi has opened NYU and Sorbonne campuses, Riyadh attracts foreign researchers with generous financial packages.
These choices are bearing fruit, but slowly.
The other difference concerns regulation. Biotech requires credible regulatory agencies to approve clinical trials, certify products, and attract international partners who cannot afford to work in legally uncertain environments. Saudi Arabia has accelerated modernization of its health agencies since 2020, and the Emirates have created free zones with specific regulatory regimes. These structures exist on paper; their international credibility will take several more years to consolidate.
From Laboratory to Factory: The 2026 Shift
The timing of this pivot is not arbitrary. Certain recent segments of biotechnology are moving toward industrialization, a movement that sector analysts have been tracking for several years.
This shift is observed on several fronts. Certain biogas or biomethane pathways can be competitive in local configurations, but advanced biofuels remain generally more expensive than fossil fuels. Genomic diagnostics are entering certain large-scale clinical programs and screening initiatives, without yet being generalized mass health products. Synthetic biology, which allows programming cells to produce molecules to specification, opens markets in fine chemicals, cosmetics, and materials.
For the Gulf, this moment is particularly relevant. Countries in the region have industrial infrastructure accustomed to large-scale processes: oil refining, petrochemicals, ammonia and urea production. Large-scale bioproduction shares process logic with these industries: tanks, controlled reactions, rigorous quality management. The learning curve is real, but the distance is not infinite.
Quantum computing, meanwhile, remains further from industrial deployment. Current machines from IBM, Google, and IonQ produce interesting results on research problems, but large-scale commercial applications can still be counted on one hand. The interest of sovereign wealth funds at this stage includes both strategic positioning and the search for future applications: taking early stakes, forming partnerships with research centers, and ensuring preferential access when applications mature.
The Risks of the Pivot: Concentrated Gains and Limited Absorption
Investing in cutting-edge technology sectors does not guarantee transforming an economy. Robotization has shown that the gains from technological change can concentrate at the top and leave most workers without net benefit. The Gulf runs an analogous risk: financing biotech and quantum assets as financial investors, without these investments generating significant local capacity in terms of skilled jobs, patents, or industrial expertise.
This risk is not hypothetical. Gulf sovereign wealth funds have invested massively in entertainment, sports, and global real estate for the past twenty years. These investments have produced financial returns, sometimes spectacular, but limited technology transfer. Biotech could follow this model if the strategy remains that of a financial portfolio rather than an industrial project.
The distinction is precise. A financial portfolio simply holds stakes in Moderna, Illumina, or a California quantum computing startup. An industrial project builds local capacities: bioproduction units on national territory, research centers with locally trained researchers, university partnerships that produce PhDs, and regulation that allows experimentation. Saudi Arabia and the Emirates appear to want the second model, but signals remain mixed.
The administration of eleven Saudi ministries under AI illustrates this tension: the ambition to deploy advanced technologies in public services is real, but deployment still relies largely on foreign suppliers and architectures designed elsewhere.
The Coming Years Will Be Decisive
Biotech takes time. Singapore took twenty years to move from political project to world-recognized pharmaceutical industry. Gulf countries are launching this bet with capital far superior to what Singapore had mobilized at the time, but in a context of more intense global competition: China, India, and Israel have all invested massively in life sciences since 2020, and the United States remains the center of gravity in the sector.
A few indicators will allow measurement of whether the strategy goes beyond the stage of financial positioning: the number of patents filed by researchers affiliated with Gulf institutions in the relevant domains, the capacity of regional universities to place their PhD graduates in local companies rather than abroad, the volume of biological production conducted on national territory, and the trajectory of startups like Mastiska beyond their first funding round.
The bet is neither won nor lost. Conditions for success exist in part. What is still missing can be built, but this presupposes holding an institutional course over a decade, and recognizing that industrial projects generally present return profiles different from those of financial portfolios. The sovereign wealth funds in question already officially display joint objectives of financial return and economic or industrial development, with variable trade-offs depending on the projects.
Sources
- Middle East Briefing / China Briefing, “Middle East Tech 2026: 5 Non-AI Trends Businesses Should Watch”, https://www.middleeastbriefing.com/news/middle-east-tech-2026-5-non-ai-trends-businesses/
- Middle East Institute, reports on Gulf economic diversification, 2026, https://www.mei.edu
- Mubadala Investment Company, technology and life sciences portfolio, https://www.mubadala.com
- Agency for Science, Technology and Research (A*STAR), Singapore, history of the Biopolis program (comparative reference source, no guaranteed link)
- IBM Quantum, state of quantum computing in 2026, https://www.ibm.com/quantum
